Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression

AIDS

Volumn 14, Issue 10, 2000, Pages 1357-1363

  Hatano, Hiroyu ^d   Vogel, Susan ^d   Yoder, Christian ^a   Metcalf, Julia A ^d   Dewar, Robin ^b   Davey Jr , Richard T ^d   Polis, Michael A ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NONE

Author keywords

Highly active antiretroviral therapy; HIV; Viral load; Viral load setpoint

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; VIREMIA;

EID: 0000228695     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007070-00008     Document Type: Article

References (33)

1. 1. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
2. 2. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. J Am Med Assoc 1999, 282: 1633-1637.
3. 3. Chiasson MA, Berenson L, Li W, et al. Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr 1999, 21:59-64.
4. 4. Pallella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Engl J Med 1998, 338:853-860.
5. 5. Rosenberg ES, LaRosa L, Flynn T, Robbins G, Walker BD. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunol Lett 1999, 66:89-93.
6. 6. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94:13193-13197.
7. 7. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
8. 8. Natarajan V, Bosche M, Metcalf JA, et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART, Lancer 1999, 353:119-120.
9. 9. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. New Engl J Med 1999, 340:1614-1622.
10. 10. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. New Engl J Med 1999, 340:1605-1613.
11. 11. Grossman Z, Polis M, Feinberg MB, et al. Ongoing HIV dissemination during HAART. Nature Med 1999, 5:1099-1104.
12. 12. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J Am Med Assoc 1999, 282:1627-1632.
13. 13. Chun TW, Davey RT, Jr., Engel D, Lane HC, Fauci AS. Reemergence of HIV after stopping therapy. Nature 1999, 401:874-875.
14. 14. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
15. 15. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1999, 5:512-517.
16. 16. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999, 13:F79-F86.
17. 17. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999, 13:677-683.
18. 18. Davey RT, Jr., Bhat N, Yoder C, et al. HIV-1 and T cell dynamics following interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999, 96:15109-15114.
19. 19. Miller V, Rottmann C, Hertogs K, et al. Mega-HAART, resistance and drug holidays. Second International Workshop on Salvage Therapy for HIV Infection. Toronto, May 1999 [abstract 030].
20. 20. Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1 infected patients after longterm viral suppression. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco. February 2000 [abstract 354].
21. 21. Lyles CM, Dorrucci M, Vlahov D, et al. Longitudinal human immunodeficiency virus type 1 load in the Italian Seroconversion Study: correlates and temporal trends of virus load. J Infect Dis 1999, 180:1018-1024.
22. 22. O'Brien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Def Syndr Hum Retrovirol 1998, 18:155-161.
23. 23. de Jong MD, de Boer RJ, de Wolf F, et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997, 11:F79-F84.
24. 24. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. New Engl J Med 1995, 332:567-575.
25. 25. Davey RT, Jr., Chaitt DC, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997, 175:781-789.
26. 26. Vidal C, Garcia F, Romeu J, et al. Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection. AIDS 1998, 12:1285-1289.
27. 27. Brambilla D, Reichelderfer PS, Bremer JW, et al. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurement. AIDS 1999, 13:2269-2279.
28. 28. Griffith BP, Rigsby MO, Garner RB, Gordon MM, Chacko TM. Comparison of the Amplicor HIV-1 monitor test and the nucleic acid sequence-based amplification assay for quantitation of human immunodeficiency virus RNA in plasma, serum, and plasma subjected to freeze-thaw cycles. J Clin Microbiol 1997, 35:3288-3291.
29. 29. Ginocchio CC, Wang XP, Kaplan MH, et al. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol 1997, 35:2886-2893.
30. 30. Rodriguez RJ, Dayhoff DE, Chang G, et al. Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:49-53.
31. 31. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
32. 32. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving protease inhibitors. AIDS 1998, 12:F51-F58.
33. 33. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999, 131:548.